Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia
The aim of the present study was first to isolate from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. positive patients received standard triple therapy...
Saved in:
| Published in: | Microbiology spectrum Vol. 12; no. 8; p. e0040124 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
American Society for Microbiology
06-08-2024
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The aim of the present study was first to isolate
from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia.
positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for
by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for
. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8%
= 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in
has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating
infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%-19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. |
|---|---|
| AbstractList | The aim of the present study was first to isolate
Helicobacter pylori
from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia.
H. pylori
positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for
H. pylori
by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for
H. pylori
. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8%
P
= 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen. The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%-19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns.The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%-19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. The aim of the present study was first to isolate from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for . Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%-19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%–19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. Antibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%–19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. ABSTRACT The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%–19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns. |
| Author | Castañeda-Chavez, Luis Javier Santacruz-Ibarra, Jorge Javier Guaca-Gonzalez, Yina Marcela Moncayo-Ortiz, José Ignacio Alvarez-Aldana, Adalucy Londoño-Giraldo, Lina María Mejía Valencia, Tatiana Fernandez Uribe, Paula Andrea Arturo-Arias, Brenda Lucia Pacheco-López, Robinson |
| Author_xml | – sequence: 1 givenname: Adalucy orcidid: 0000-0001-7460-4163 surname: Alvarez-Aldana fullname: Alvarez-Aldana, Adalucy organization: Grupo de Investigación en Microbiología y Biotecnología (MICROBIOTEC), Universidad Libre Seccional Pereira, Pereira, Colombia – sequence: 2 givenname: Paula Andrea surname: Fernandez Uribe fullname: Fernandez Uribe, Paula Andrea organization: Grupo de Investigación ESCULAPIO, Universidad Libre Seccional Cali, Cali, Colombia – sequence: 3 givenname: Tatiana surname: Mejía Valencia fullname: Mejía Valencia, Tatiana organization: Grupo de Investigación en Gerencia del Cuidado, Universidad Libre Seccional Pereira, Pereira, Colombia – sequence: 4 givenname: Yina Marcela surname: Guaca-Gonzalez fullname: Guaca-Gonzalez, Yina Marcela organization: Grupo de Investigación en Enfermedades Infecciosas (GRIENI), Universidad Tecnológica de Pereira, Pereira, Colombia – sequence: 5 givenname: Jorge Javier surname: Santacruz-Ibarra fullname: Santacruz-Ibarra, Jorge Javier organization: Grupo de Investigación en Enfermedades Infecciosas (GRIENI), Universidad Tecnológica de Pereira, Pereira, Colombia – sequence: 6 givenname: Brenda Lucia surname: Arturo-Arias fullname: Arturo-Arias, Brenda Lucia organization: SES Hospital Universitario de Caldas, Manizales, Colombia – sequence: 7 givenname: Luis Javier surname: Castañeda-Chavez fullname: Castañeda-Chavez, Luis Javier organization: Centro de Especialistas de Risaralda, Pereira, Colombia – sequence: 8 givenname: Robinson surname: Pacheco-López fullname: Pacheco-López, Robinson organization: Grupo de Investigación ESCULAPIO, Universidad Libre Seccional Cali, Cali, Colombia – sequence: 9 givenname: Lina María orcidid: 0000-0002-7824-0245 surname: Londoño-Giraldo fullname: Londoño-Giraldo, Lina María organization: Grupo de Investigación en Microbiología y Biotecnología (MICROBIOTEC), Universidad Libre Seccional Pereira, Pereira, Colombia – sequence: 10 givenname: José Ignacio surname: Moncayo-Ortiz fullname: Moncayo-Ortiz, José Ignacio organization: Grupo de Investigación en Enfermedades Infecciosas (GRIENI), Universidad Tecnológica de Pereira, Pereira, Colombia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38916348$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQHKEgEkI-gAvykcsufs2LC4oiIJEicYGz1bZ7Nl55xoPtIdq_4VPxZjdRcuFku6u62t1db6uTKUxYVe8ZXTPGu09pRpPjMq4plZStuHxVnXHW1Csq-_bk2f20ukhpSylljNa85m-qU9H1rBGyO6v-Xk7Zjc7EoB14kpZkcM5OO-_yjoSBGO8mZwp0jd6ZoMFkjGTe-RAdcSl4yJgITJa4nAhGsIWdXZiI3pGUCwDRkhzd7JHku0KYd58JFGixO-Imco8pE4NTjqVIxM0-tdS9Cj6M5U_vqtcD-IQXx_O8-vXt68-r69Xtj-83V5e3KxBdm1eCW11rabuasabnGntjNNgSFdhK2yAO3QAGtTZ9KzRQWV6cAgorWd9JcV7dHHRtgK2aoxsh7lQApx4CIW4UxOyMR2WBMdFAg6xvZNNJGFpgRY0jb0XNTdH6ctCaFz2iPTb3QvQlMrk7tQl_VNGlvGlYUfh4VIjh91ImpEZXNuM9TBiWpARteVmo7NpCZQdq2WFKEYenOoyqvVPUo1PUg1MU3ze7PuRAGrnahiVOZbb_TfjwvKOnEo9GEv8AW4HS3w |
| Cites_doi | 10.3389/fcimb.2017.00168 10.3390/antibiotics9030121 10.1177/00469580231154650 10.3390/pathogens10091099 10.1136/gutjnl-2015-309252 10.3390/antibiotics12020191 10.3748/wjg.15.1528 10.7705/biomedica.v39i4.4377 10.1155/2018/9064952 10.3390/antibiotics12020332 10.11144/Javeriana.umed59-3.pylo 10.1136/gutjnl-2022-327745 10.1136/gutjnl-2021-324032 10.1099/0022-1317-52-12-1129 10.1053/j.gastro.2018.07.007 10.1111/apt.14561 10.14309/ctg.0000000000000194 10.3748/wjg.v24.i14.1531 10.1038/s41572-023-00431-8 10.1186/s13104-019-4877-9 10.1007/s12275-013-2465-6 10.7705/biomedica.v39i3.4437 10.22516/25007440.493 10.1128/AAC.00145-09 10.1371/journal.pone.0160007 10.5009/gnl210365 10.1080/17512433.2019.1654858 10.1136/gutjnl-2016-312288 10.1128/JCM.03203-20 10.1186/s13104-018-3919-z 10.3390/life12122038 10.3389/fmicb.2022.1008346 10.5114/pg.2020.101557 10.37768/unw.rinv.11.02.a0016 10.1159/000503381 10.5009/gnl18137 10.1111/hel.12936 10.3390/ijms24065776 10.1016/j.ejim.2022.01.029 |
| ContentType | Journal Article |
| Contributor | Gopalakrishnan, Vinoj |
| Contributor_xml | – sequence: 1 givenname: Vinoj surname: Gopalakrishnan fullname: Gopalakrishnan, Vinoj |
| Copyright | Copyright © 2024 Alvarez-Aldana et al. Copyright © 2024 Alvarez-Aldana et al. 2024 Alvarez-Aldana et al. |
| Copyright_xml | – notice: Copyright © 2024 Alvarez-Aldana et al. – notice: Copyright © 2024 Alvarez-Aldana et al. 2024 Alvarez-Aldana et al. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1128/spectrum.00401-24 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology Public Health |
| EISSN | 2165-0497 |
| Editor | Powell, Eleanor A. |
| Editor_xml | – sequence: 1 givenname: Eleanor A. surname: Powell fullname: Powell, Eleanor A. |
| ExternalDocumentID | oai_doaj_org_article_da1136a6e1964684af7a1ac22e27352c 10_1128_spectrum_00401_24 00401-24 38916348 |
| Genre | Journal Article |
| GeographicLocations | Colombia |
| GeographicLocations_xml | – name: Colombia |
| GrantInformation_xml | – fundername: Universidad Tecnológica de Pereira (UTP) grantid: CIE 5-17-4 – fundername: Universidad Tecnológica de Pereira (UTP) grantid: CIE 5-17-4 funderid: https://doi.org/10.13039/501100013367 – fundername: ; grantid: CIE 5-17-4 |
| GroupedDBID | 53G AAUOK ADBBV AGVNZ ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF EJD FF~ FRP GROUPED_DOAJ H13 M~E NPM OK1 RPM RSF UCJ AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-a387t-32db5b4d8511692be9ccbad2db3e74d6eef8facebbc973ba04fac20ae3d419843 |
| IEDL.DBID | RPM |
| ISSN | 2165-0497 |
| IngestDate | Tue Oct 22 15:08:44 EDT 2024 Tue Sep 17 21:28:35 EDT 2024 Sat Oct 26 04:26:12 EDT 2024 Fri Nov 22 02:40:20 EST 2024 Tue Aug 06 18:20:14 EDT 2024 Sat Nov 02 12:27:41 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Colombia drug therapy Helicobacter pylori antibiotics eradication resistance |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a387t-32db5b4d8511692be9ccbad2db3e74d6eef8facebbc973ba04fac20ae3d419843 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
| ORCID | 0000-0002-7824-0245 0000-0001-7460-4163 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302661/ |
| PMID | 38916348 |
| PQID | 3072001487 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_da1136a6e1964684af7a1ac22e27352c pubmedcentral_primary_oai_pubmedcentral_nih_gov_11302661 proquest_miscellaneous_3072001487 crossref_primary_10_1128_spectrum_00401_24 asm2_journals_10_1128_spectrum_00401_24 pubmed_primary_38916348 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-06 |
| PublicationDateYYYYMMDD | 2024-08-06 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Spectrum |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2024 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | Martínez, JD, Henao, SC, Lizarazo, JI (B33) 2014; 29 Otero-Regino, W, Trespalacios, AA, Otero, E (B36) 2009; 24 Kumar, S, Patel, GK, Ghoshal, UC (B6) 2021; 10 Vainio, H (B8) 1994; 61 Kim, JL, Cho, SJ, Chung, SJ, Lee, A, Choi, J, Chung, H, Kim, SG (B26) 2020; 11 Boyanova, L, Hadzhiyski, P, Kandilarov, N, Markovska, R, Mitov, I (B44) 2019; 12 Mannion, A, Dzink-Fox, J, Shen, Z, Piazuelo, MB, Wilson, KT, Correa, P, Peek, RM, Camargo, MC, Fox, JG (B39) 2021; 59 Malfertheiner, P, Megraud, F, Rokkas, T, Gisbert, JP, Liou, J-M, Schulz, C, Gasbarrini, A, Hunt, RH, Leja, M, O’Morain, C, Rugge, M, Suerbaum, S, Tilg, H, Sugano, K, El-Omar, EM (B10) 2022 Matta, AJ, Zambrano, DC, Pazos, AJ (B29) 2018; 24 Roberts, LT, Issa, PP, Sinnathamby, ES, Granier, M, Mayeux, H, Eubanks, TN, Malone, K, Ahmadzadeh, S, Cornett, EM, Shekoohi, S, Kaye, AD (B42) 2022; 12 Hu, Y, Zhu, Y, Lu, NH (B9) 2017; 7 Mejía Valencia, T, Arturo Arias, BL, Álvarez Aldana, A, Moncayo Ortiz, JI, Santacruz Ibarra, JJ, Guaca Gonzales, YM, Pacheco López, R (B2) 2023; 12 Savoldi, A, Carrara, E, Graham, DY, Conti, M, Tacconelli, E (B12) 2018; 155 Manfredi, M, Gismondi, P, Iuliano, S (B5) 2023; 60 Seo, SI, Lim, H, Bang, CS, Yang, YJ, Baik, GH, Lee, SP, Jang, HJ, Kae, SH, Kim, J, Kim, HY, Shin, WG (B27) 2022; 16 Roldán, IJ, Castaño, R, Navas, MC (B30) 2019; 39 Bassetti, S, Tschudin-Sutter, S, Egli, A, Osthoff, M (B43) 2022; 99 Zamani, M, Ebrahimtabar, F, Zamani, V, Miller, WH, Alizadeh-Navaei, R, Shokri-Shirvani, J, Derakhshan, MH (B1) 2018; 47 Di Fermo, P, Di Lodovico, S, Di Campli, E, D’Arcangelo, S, Diban, F, D’Ercole, S, Di Giulio, M, Cellini, L (B23) 2023; 24 Megraud, F, Bruyndonckx, R, Coenen, S, Wittkop, L, Huang, T-D, Hoebeke, M, Bénéjat, L, Lehours, P, Goossens, H, Glupczynski, Y (B35) 2021; 70 Boyanova, L (B21) 2003; 52 Yin, Y, He, LH, Zhang, JZ (B20) 2009; 15 Malfertheiner, P, Camargo, MC, El-Omar, E, Liou, J-M, Peek, R, Schulz, C, Smith, SI, Suerbaum, S (B4) 2023; 9 Zhong, Z, Wang, X, Li, J, Zhang, B, Yan, L, Xu, S, Chen, G, Gao, H (B22) 2022; 13 Gladyshev, N, Taame, M, Kravtsov, V (B24) 2020; 15 Sugano, K, Tack, J, Kuipers, EJ, Graham, DY, El-Omar, EM, Miura, S, Haruma, K, Asaka, M, Uemura, N, Malfertheiner, P (B7) 2015; 64 Rokkas, T, Ekmektzoglou, K, Graham, DY (B41) 2023; 28 Alvarez, A, Moncayo, JI, Santacruz, JJ, Santacoloma, M, Corredor, LF, Reinosa, E (B17) 2009; 53 Miftahussurur, M, Fauzia, KA, Nusi, IA, Setiawan, PB, Syam, AF, Waskito, LA, Doohan, D, Ratnasari, N, Khomsan, A, Adnyana, IK, Akada, J, Yamaoka, Y (B25) 2020; 13 Trespalacios-Rangél, AA, Otero, W, Arévalo-Galvis, A, Poutou-Piñales, RA, Rimbara, E, Graham, DY (B37) 2016; 11 B15 Malfertheiner, P, Megraud, F, O’Morain, CA, Gisbert, JP, Kuipers, EJ, Axon, AT, Bazzoli, F, Gasbarrini, A, Atherton, J, Graham, DY, Hunt, R, Moayyedi, P, Rokkas, T, Rugge, M, Selgrad, M, Suerbaum, S, Sugano, K, El-Omar, EM (B28) 2017; 66 Arévalo, A, Otero, WA, Trespalacios, AA (B38) 2019; 39 Aguilar-Luis, MA, Palacios-Cuervo, F, Espinal-Reyes, F, Calderón-Rivera, A, Levy-Blitchtein, S, Palomares-Reyes, C, Silva-Caso, W, Zavaleta-Gavidia, V, Bazán-Mayra, J, Cornejo-Tapia, A, Del Valle-Mendoza, J, Del Valle, LJ (B34) 2018; 11 Boyanova, L, Hadzhiyski, P, Gergova, R, Markovska, R (B13) 2023; 12 Trespalacios, AA, Otero, W, Caminos, JE, Mercado, MM, Avila, J, Rosero, LE, Arévalo, A, Poutou-Piñales, RA, Graham, DY (B32) 2013; 51 Atehortúa-Rendón, JD, Martínez, A, Pérez Cala, TL (B31) 2020; 35 Talebi Bezmin Abadi, A (B19) 2018; 2018 Khien, VV, Thang, DM, Hai, TM, Duat, NQ, Khanh, PH, Ha, DT, Binh, TT, Dung, HDQ, Trang, TTH, Yamaoka, Y (B40) 2019; 13 Bedoya-Gómez, IJ, Alvarez-Aldana, A, Moncayo-Ortiz, JI, Guaca-González, YM, Santacruz-Ibarra, JJ, Arturo-Arias, BL, Castañeda-Chávez, LJ, Leon Rodriguez, DA, Beltrán-Angarita, L (B16) 2020; 38 Saracino, IM, Pavoni, M, Zullo, A, Fiorini, G, Saccomanno, L, Lazzarotto, T, Cavallo, R, Antonelli, G, Vaira, D (B11) 2020; 9 (B14) 2016 Laserna Estrada, AF, Barahona Correa, JE, Alba Talero, LH (B18) 2018; 59 Elbehiry, A, Marzouk, E, Aldubaib, M, Abalkhail, A, Anagreyyah, S, Anajirih, N, Almuzaini, AM, Rawway, M, Alfadhel, A, Draz, A, Abu-Okail, A (B3) 2023; 12 e_1_3_6_30_2 e_1_3_6_31_2 e_1_3_6_32_2 e_1_3_6_10_2 e_1_3_6_19_2 Otero-Regino W (e_1_3_6_37_2) 2009; 24 e_1_3_6_14_2 e_1_3_6_13_2 e_1_3_6_38_2 e_1_3_6_12_2 e_1_3_6_39_2 e_1_3_6_11_2 e_1_3_6_18_2 e_1_3_6_33_2 e_1_3_6_17_2 e_1_3_6_16_2 e_1_3_6_35_2 e_1_3_6_36_2 e_1_3_6_41_2 e_1_3_6_40_2 e_1_3_6_20_2 e_1_3_6_43_2 e_1_3_6_21_2 e_1_3_6_42_2 Martínez JD (e_1_3_6_34_2) 2014; 29 e_1_3_6_5_2 e_1_3_6_4_2 Vainio H (e_1_3_6_9_2) 1994 CLSI (e_1_3_6_15_2) 2016 e_1_3_6_3_2 e_1_3_6_2_2 e_1_3_6_8_2 e_1_3_6_7_2 e_1_3_6_6_2 e_1_3_6_26_2 e_1_3_6_27_2 e_1_3_6_28_2 e_1_3_6_29_2 e_1_3_6_22_2 e_1_3_6_45_2 e_1_3_6_23_2 e_1_3_6_44_2 e_1_3_6_24_2 e_1_3_6_25_2 |
| References_xml | – volume: 7 year: 2017 ident: B9 article-title: Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance publication-title: Front. Cell. Infect. Microbiol doi: 10.3389/fcimb.2017.00168 contributor: fullname: Lu, NH – year: 2016 ident: B14 article-title: Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria publication-title: CLSI guideline M45 ;3 ;In ;Clinical and Laboratory Standards Institute – ident: B15 article-title: The European Committee on Antimicrobial Susceptibility Testing . 2023 . Breakpoint tables for interpretation of mics and zone diameters . Version 13.1 . Available from : https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf – volume: 9 year: 2020 ident: B11 article-title: Antibiotic resistance and therapy outcome in H. pylori eradication failure patients publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics9030121 contributor: fullname: Vaira, D – volume: 60 start-page: 469580231154650 year: 2023 ident: B5 article-title: Is Helicobacter pylori anyway pathogen in children? publication-title: Inquiry doi: 10.1177/00469580231154650 contributor: fullname: Iuliano, S – volume: 10 start-page: 1099 year: 2021 ident: B6 article-title: Helicobacter pylori-induced inflammation: possible factors modulating the risk of gastric cancer publication-title: Pathogens doi: 10.3390/pathogens10091099 contributor: fullname: Ghoshal, UC – volume: 64 start-page: 1353 year: 2015 end-page: 1367 ident: B7 article-title: Kyoto global consensus report on Helicobacter pylori gastritis publication-title: Gut doi: 10.1136/gutjnl-2015-309252 contributor: fullname: Malfertheiner, P – volume: 12 start-page: 191 year: 2023 ident: B3 article-title: Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges publication-title: Antibiotics doi: 10.3390/antibiotics12020191 contributor: fullname: Abu-Okail, A – volume: 15 start-page: 1528 year: 2009 end-page: 1529 ident: B20 article-title: Successful isolation of Helicobacter pylori after prolonged incubation from a patient with failed eradication therapy publication-title: World J Gastroenterol doi: 10.3748/wjg.15.1528 contributor: fullname: Zhang, JZ – volume: 39 start-page: 117 year: 2019 end-page: 129 ident: B30 article-title: Mutaciones del gen ARN ribosómico 23S de Helicobacter pylori asociadas con resistencia a claritromicina en pacientes atendidos en una unidad de endoscopia de medellín, Colombia. biomedica: revista del Instituto Nacional de Salud publication-title: biomedica doi: 10.7705/biomedica.v39i4.4377 contributor: fullname: Navas, MC – volume: 2018 year: 2018 ident: B19 article-title: Diagnosis of Helicobacter pylori using invasive and noninvasive approaches publication-title: J Pathog doi: 10.1155/2018/9064952 contributor: fullname: Talebi Bezmin Abadi, A – volume: 12 year: 2023 ident: B13 article-title: Evolution of Helicobacter pylori resistance to antibiotics: a topic of increasing concern publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics12020332 contributor: fullname: Markovska, R – volume: 59 start-page: 1 year: 2018 end-page: 13 ident: B18 article-title: Manejo de la infección por Helicobacter pylori: apreciación crítica de la literatura publication-title: Univ Med doi: 10.11144/Javeriana.umed59-3.pylo contributor: fullname: Alba Talero, LH – year: 2022 ident: B10 article-title: Management of Helicobacter pylori infection: the maastricht VI/Florence consensus report publication-title: Gut doi: 10.1136/gutjnl-2022-327745 contributor: fullname: El-Omar, EM – volume: 70 start-page: 1815 year: 2021 end-page: 1822 ident: B35 article-title: Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community publication-title: Gut doi: 10.1136/gutjnl-2021-324032 contributor: fullname: Glupczynski, Y – volume: 52 start-page: 1129 year: 2003 end-page: 1130 ident: B21 article-title: Influence of transport conditions and media on Helicobacter pylori isolation publication-title: J Med Microbiol doi: 10.1099/0022-1317-52-12-1129 contributor: fullname: Boyanova, L – volume: 155 start-page: 1372 year: 2018 end-page: 1382 ident: B12 article-title: Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.07.007 contributor: fullname: Tacconelli, E – volume: 47 start-page: 868 year: 2018 end-page: 876 ident: B1 article-title: Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14561 contributor: fullname: Derakhshan, MH – volume: 11 year: 2020 ident: B26 article-title: Empiric versus clarithromycin resistance-guided therapy for Helicobacter pylori based on polymerase chain reaction results in patients with gastric neoplasms or gastric mucosa-associated lymphoid tissue lymphoma: a randomized controlled trial publication-title: Clin Transl Gastroenterol doi: 10.14309/ctg.0000000000000194 contributor: fullname: Kim, SG – volume: 24 start-page: 1531 year: 2018 end-page: 1539 ident: B29 article-title: Punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori in Colombian populations publication-title: World J Gastroenterol doi: 10.3748/wjg.v24.i14.1531 contributor: fullname: Pazos, AJ – volume: 9 start-page: 19 year: 2023 ident: B4 article-title: Helicobacter pylori infection publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-023-00431-8 contributor: fullname: Suerbaum, S – volume: 13 year: 2020 ident: B25 article-title: E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study publication-title: BMC Res Notes doi: 10.1186/s13104-019-4877-9 contributor: fullname: Yamaoka, Y – volume: 51 start-page: 448 year: 2013 end-page: 452 ident: B32 article-title: Phenotypic and genotypic analysis of Clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia publication-title: J Microbiol doi: 10.1007/s12275-013-2465-6 contributor: fullname: Graham, DY – volume: 39 start-page: 125 year: 2019 end-page: 134 ident: B38 article-title: Helicobacter pylori: multiple resistance in patients from Bogotá-Colombia publication-title: Biomedica doi: 10.7705/biomedica.v39i3.4437 contributor: fullname: Trespalacios, AA – volume: 35 start-page: 351 year: 2020 end-page: 361 ident: B31 article-title: Helicobacter pylori susceptibility to six commonly used antibiotics in Colombia publication-title: Rev Colomb Gastroenterol doi: 10.22516/25007440.493 contributor: fullname: Pérez Cala, TL – volume: 53 start-page: 4022 year: 2009 end-page: 4024 ident: B17 article-title: Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00145-09 contributor: fullname: Reinosa, E – volume: 11 year: 2016 ident: B37 article-title: Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009-2014) publication-title: PLoS One doi: 10.1371/journal.pone.0160007 contributor: fullname: Graham, DY – volume: 16 start-page: 697 year: 2022 end-page: 705 ident: B27 article-title: Bismuth-based quadruple therapy versus metronidazole-intensified triple therapy as a first-line treatment for clarithromycin-resistant Helicobacter pylori infection: a multicenter randomized controlled trial publication-title: Gut Liver doi: 10.5009/gnl210365 contributor: fullname: Shin, WG – volume: 12 start-page: 909 year: 2019 end-page: 915 ident: B44 article-title: Multidrug resistance in Helicobacter pylori: current state and future directions publication-title: Expert Rev Clin Pharmacol doi: 10.1080/17512433.2019.1654858 contributor: fullname: Mitov, I – volume: 61 start-page: 1 year: 1994 end-page: 241 ident: B8 article-title: Schistosomes, liver flukes, and Helicobacter Pylori publication-title: IARC monographs on the evaluation of carcinogenic risks to humans ;p In Vol contributor: fullname: Vainio, H – volume: 24 start-page: 279 year: 2009 end-page: 292 ident: B36 article-title: Helicobacter Pylori: current treatment an important challenge for gastroenterology publication-title: Rev Colomb Gastroenterol contributor: fullname: Otero, E – volume: 66 start-page: 6 year: 2017 end-page: 30 ident: B28 article-title: Management of Helicobacter pylori infection-the maastricht v/florence consensus report publication-title: Gut doi: 10.1136/gutjnl-2016-312288 contributor: fullname: El-Omar, EM – volume: 59 year: 2021 ident: B39 article-title: Helicobacter pylori antimicrobial resistance and gene variants in high- and low-gastric-cancer-risk populations publication-title: J Clin Microbiol doi: 10.1128/JCM.03203-20 contributor: fullname: Fox, JG – volume: 29 start-page: 218 year: 2014 end-page: 227 ident: B33 article-title: Resistencia antibiótica del Helicobacter pylori en América Latina Y El Caribe publication-title: Rev Colomb Gastroenterol contributor: fullname: Lizarazo, JI – volume: 11 year: 2018 ident: B34 article-title: Highly clarithromycin-resistant Helicobacter pylori infection in asymptomatic children from a rural community of Cajamarca-Peru publication-title: BMC Res Notes doi: 10.1186/s13104-018-3919-z contributor: fullname: Del Valle, LJ – volume: 12 year: 2022 ident: B42 article-title: Helicobacter pylori: a review of current treatment options in clinical practice publication-title: Life (Basel) doi: 10.3390/life12122038 contributor: fullname: Kaye, AD – volume: 13 start-page: 1008346 year: 2022 ident: B22 article-title: A study on the diagnosis of the Helicobacter pylori coccoid form with artificial intelligence technology publication-title: Front Microbiol doi: 10.3389/fmicb.2022.1008346 contributor: fullname: Gao, H – volume: 15 start-page: 294 year: 2020 end-page: 300 ident: B24 article-title: Clinical and laboratory importance of detecting Helicobacter pylori coccoid forms for the selection of treatment publication-title: Prz Gastroenterol doi: 10.5114/pg.2020.101557 contributor: fullname: Kravtsov, V – volume: 12 year: 2023 ident: B2 article-title: Prevalence, clinical and demographic characteristics of Helicobacter pylori in patients undergoing esophagogastroduodenoscopy in specialized health centers in two departments of the Colombian coffee growing axis publication-title: Rev Inv UNW doi: 10.37768/unw.rinv.11.02.a0016 contributor: fullname: Pacheco López, R – volume: 38 start-page: 196 year: 2020 end-page: 203 ident: B16 article-title: Surveillance of the antimicrobial resistance rates of Helicobacter pylori ten years later in the western central region, Colombia publication-title: Dig Dis doi: 10.1159/000503381 contributor: fullname: Beltrán-Angarita, L – volume: 13 start-page: 483 year: 2019 end-page: 497 ident: B40 article-title: Management of antibiotic-resistant Helicobacter pylori infection: perspectives from Vietnam publication-title: Gut Liver doi: 10.5009/gnl18137 contributor: fullname: Yamaoka, Y – volume: 28 year: 2023 ident: B41 article-title: Current role of tailored therapy in treating Helicobacter pylori infections. a systematic review, meta-analysis and critical analysis publication-title: Helicobacter doi: 10.1111/hel.12936 contributor: fullname: Graham, DY – volume: 24 year: 2023 ident: B23 article-title: Helicobacter pylori dormant states are affected by vitamin C publication-title: Int J Mol Sci doi: 10.3390/ijms24065776 contributor: fullname: Cellini, L – volume: 99 start-page: 7 year: 2022 end-page: 12 ident: B43 article-title: Optimizing antibiotic therapies to reduce the risk of bacterial resistance publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2022.01.029 contributor: fullname: Osthoff, M – start-page: 1 volume-title: IARC monographs on the evaluation of carcinogenic risks to humans year: 1994 ident: e_1_3_6_9_2 contributor: fullname: Vainio H – ident: e_1_3_6_18_2 doi: 10.1128/AAC.00145-09 – ident: e_1_3_6_23_2 doi: 10.3389/fmicb.2022.1008346 – ident: e_1_3_6_11_2 doi: 10.1136/gutjnl-2022-327745 – ident: e_1_3_6_32_2 doi: 10.22516/25007440.493 – ident: e_1_3_6_44_2 doi: 10.1016/j.ejim.2022.01.029 – ident: e_1_3_6_6_2 doi: 10.1177/00469580231154650 – ident: e_1_3_6_12_2 doi: 10.3390/antibiotics9030121 – ident: e_1_3_6_41_2 doi: 10.5009/gnl18137 – ident: e_1_3_6_45_2 doi: 10.1080/17512433.2019.1654858 – ident: e_1_3_6_39_2 doi: 10.7705/biomedica.v39i3.4437 – ident: e_1_3_6_10_2 doi: 10.3389/fcimb.2017.00168 – ident: e_1_3_6_17_2 doi: 10.1159/000503381 – volume: 24 start-page: 279 year: 2009 ident: e_1_3_6_37_2 article-title: Helicobacter Pylori: current treatment an important challenge for gastroenterology publication-title: Rev Colomb Gastroenterol contributor: fullname: Otero-Regino W – ident: e_1_3_6_2_2 doi: 10.1111/apt.14561 – ident: e_1_3_6_3_2 doi: 10.37768/unw.rinv.11.02.a0016 – ident: e_1_3_6_35_2 doi: 10.1186/s13104-018-3919-z – ident: e_1_3_6_20_2 doi: 10.1155/2018/9064952 – ident: e_1_3_6_8_2 doi: 10.1136/gutjnl-2015-309252 – volume: 29 start-page: 218 year: 2014 ident: e_1_3_6_34_2 article-title: Resistencia antibiótica del Helicobacter pylori en América Latina Y El Caribe publication-title: Rev Colomb Gastroenterol contributor: fullname: Martínez JD – ident: e_1_3_6_21_2 doi: 10.3748/wjg.15.1528 – ident: e_1_3_6_16_2 – ident: e_1_3_6_19_2 doi: 10.11144/Javeriana.umed59-3.pylo – ident: e_1_3_6_26_2 doi: 10.1186/s13104-019-4877-9 – ident: e_1_3_6_36_2 doi: 10.1136/gutjnl-2021-324032 – ident: e_1_3_6_24_2 doi: 10.3390/ijms24065776 – ident: e_1_3_6_33_2 doi: 10.1007/s12275-013-2465-6 – ident: e_1_3_6_38_2 doi: 10.1371/journal.pone.0160007 – ident: e_1_3_6_42_2 doi: 10.1111/hel.12936 – ident: e_1_3_6_14_2 doi: 10.3390/antibiotics12020332 – ident: e_1_3_6_22_2 doi: 10.1099/0022-1317-52-12-1129 – ident: e_1_3_6_4_2 doi: 10.3390/antibiotics12020191 – ident: e_1_3_6_13_2 doi: 10.1053/j.gastro.2018.07.007 – ident: e_1_3_6_30_2 doi: 10.3748/wjg.v24.i14.1531 – ident: e_1_3_6_7_2 doi: 10.3390/pathogens10091099 – volume-title: CLSI guideline M45 year: 2016 ident: e_1_3_6_15_2 contributor: fullname: CLSI – ident: e_1_3_6_25_2 doi: 10.5114/pg.2020.101557 – ident: e_1_3_6_5_2 doi: 10.1038/s41572-023-00431-8 – ident: e_1_3_6_40_2 doi: 10.1128/JCM.03203-20 – ident: e_1_3_6_28_2 doi: 10.5009/gnl210365 – ident: e_1_3_6_43_2 doi: 10.3390/life12122038 – ident: e_1_3_6_27_2 doi: 10.14309/ctg.0000000000000194 – ident: e_1_3_6_29_2 doi: 10.1136/gutjnl-2016-312288 – ident: e_1_3_6_31_2 doi: 10.7705/biomedica.v39i4.4377 |
| SSID | ssj0001105252 |
| Score | 2.3471353 |
| Snippet | The aim of the present study was first to isolate
from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the... The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was... Antibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the... The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was... ABSTRACT The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility.... |
| SourceID | doaj pubmedcentral proquest crossref asm2 pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0040124 |
| SubjectTerms | Adult Aged Amoxicillin - pharmacology Amoxicillin - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use antibiotics Clarithromycin - pharmacology Clarithromycin - therapeutic use Colombia Drug Resistance, Bacterial drug therapy Drug Therapy, Combination eradication Female Helicobacter Infections - drug therapy Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - genetics Helicobacter pylori - isolation & purification Humans Levofloxacin - pharmacology Levofloxacin - therapeutic use Male Metronidazole - pharmacology Metronidazole - therapeutic use Microbial Sensitivity Tests Middle Aged Proton Pump Inhibitors - therapeutic use Public Health Research Article resistance Treatment Outcome Young Adult |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELagEhIXxJvw0iAhISGFTRzXcbgty672xAWQuFnjR0QOTVdNe-i_2Z_KjJNUW4TgwtVx7JHnsz0ej78R4q1aFq4wvsqXLrS50j7mRmOZ14VypvRoArIr-_Jr_eWH-XzONDmHVF8cEzbSA48DdxKQs46gjswcpY3CtsYSvZSRNt6l9Gn1LfSNw1TyrpScn01O15i0Bp-kh4ub3eoDw7bM-YX7AoeVPNqPEm3_n2zN30Mmb-xBF_fFvcl4hNNR6AfiVuwfijtjOsn9I3F92m-7VZeolajasBtSzEoKf93DuoX5GSTQZkMIcImpGa74zN5BRyhkwxOwD9BtB4gbDJNHD9weZqcDbDfsnIfx5db-IyAkjlroemDeBZiEB875QL9Sv2ck4Ipkeiy-X5x_O7vMpwwMOVam3uaVDG7pVGCzTDfSxcZ7h4FKq1iroGNsTYs-OuebunJYqJYpHzFWQZWNUdUTsejXfXwmoI5kmsSmjNKgolYb1cbaUQNsJBA8MvGO1WGnKTTYdDqRxs6Ks0lxVqpMvJ81Zq9GSo6_Vf7EOj1UZDbtVEAYsxPG7L8wlok3MyIszT6-UsE-rneDpRWSg9Lo1JeJpyNCDl3xDbCulMmEOcLOkSzHX_ruZ2L4Lvk6mSyn5_9D-hfirqRBTlGL-qVY0PjEV-L2EHav06T5BQRrIf8 priority: 102 providerName: Directory of Open Access Journals |
| Title | Antimicrobial susceptibility of clinical Helicobacter pylori isolates and its eradication by standard triple therapy: a study in west central region of Colombia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38916348 https://journals.asm.org/doi/10.1128/spectrum.00401-24 https://www.proquest.com/docview/3072001487 https://pubmed.ncbi.nlm.nih.gov/PMC11302661 https://doaj.org/article/da1136a6e1964684af7a1ac22e27352c |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_uguCL-G31PEYQBKG72zSbpr6d6x33oggq-BbyVS1cu8t292H_G__Um0nb41bEB1_btJl2fklmJpPfMPZGLBd2oVyeLq2vUiFdSJU0WVoshFWZM8obCmVffi0-_1Afz4kmR45nYWLSvrP1rL1qZm39K-ZWbho3H_PE5l8-rTLabcOFZT5hEzQOb_noMbKSUW02Pmxh4vw7j4cWt_tmRpDNUk7FeGh_TuZU9mdquoYfLUuRvf9vJuefmZO3lqKLB-z-YEPCWS_rQ3YntI_Y3b6q5OEx-33W7uqmjgxL2KzbdzF1JWbBHmBdwXgaEnDNQSDYSNgMG3Lda6gRjGR_gmk91LsOwtb4IbAH9gBj7AF2W4rRQ3-A6_AeDESqWqhbIPoFGIQHKv2Aj2K_KxSwQZmesO8X599Wl-lQiCE1uSp2ac69XVrhyTqTJbehdM4aj1fzUAgvQ6hUZVyw1pVFbs1CVMT8aELuRVYqkT9l03bdhucMioAWSiizwJUR-NZSVKGw-AKyFRAlCXtL6tDDSOp0dFK40qMOddSh5iJh70aN6U3PzPGvxh9IpzcNiVQ7Xlhvf-oBWtobKnBjZCCSMqmEqQqT4YfwgDbekruEvR4RoXEQ0s6KacN632mcKCk3DZ2_hD3rEXLT1Qi0hKkj7BzJcnwHcR-Jvkecv_j_R1-yexx_bUxZlCdsin8lvGKTzu9PY_jhNI6da9TdJCY |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbYIgQX3o_wHCQkJKS0ieMmDrel7KqI3RUSi8TN8isQiaRV0x76b_ipzLjJaosQh706TvyYz_HMePwNY2_ENDGJtFk8Na6KRW59LHOdxkUijEytlk6TK3v-tTj7Lj8eEU1OPtyFCUH71tTj9lczbuufIbZy2djJECc2-XI6S-m0DTeWyQG7jgs2SS5Z6cG3klJ2Nt4fYuIfeBKuLa42zZhAm8ac0vHQCV2eUeKfke4avrcxBf7-fymdf8dOXtqMju9cdRh32e1e_YTD3fN77Jpv77Mbu4SU2wfs92G7rps6kDNhtW7ThaiXEEC7hUUFw0VKwO0KMWQC1zMsyeqvoUYck-oKunVQrzvwK-16nyCYLQxuC1ivyL0Pu7tf2_egIbDcQt0CMTdAP2qgrBH4KrY7ww422KeH7Nvx0flsHvc5HGKdyWIdZ9yZqRGOFLu85MaX1hrtsDTzhXC595WstPXG2LLIjE5ERaSR2mdOpKUU2SM2ahetf8Kg8Kjc-DL1XGqBXy1F5QuDHyA1AwEWsbckR9Uvwk4F-4ZLNQhfBeErLiL2bhC1Wu5IPf5X-QOB4aIi8XGHgsXqh-rFqZym3Dg698Rvlkuhq0KnOBDuUT2cchux1wOUFK5fOpTRrV9sOoX_WAprQ7sxYo930LpoakBoxOQe6Pb6sv8EsRY4wgdsPb36q6_Yzfn56Yk6-XT2-Rm7xXGaQ-Rj_pyNcIb8C3bQuc3LsPT-AFYiON4 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYIhAX3o_wHCQkJKQ0ieMmzt6W7laLgNVKgMTNsmMHIpG0atpD_w0_lRknWW0R4gBXx3b8-GzPjMffMPZKzGITyzINZ8ZWochKF8pMJ2EeCyOTUkuryZR9-ik_-yqPT4gm53B8C-Od9ktTT9sfzbStv3vfylVTRqOfWHT-cZ7QbRseLNHKVtEBu4qLNuaXNHVvX0koQhsfLjJxF47808X1tpkScJOQU0geuqXLUgr-M9Fdw_cOJ8_h_yfB83f_yUsH0uLW_3TlNrs5iKFw1Oe5w6649i671gem3N1jP4_aTd3UnqQJs3Xbznu_eEfaHSwrGB9UAh5biCXjOZ9hRdp_DTXimURY0K2FetOBW2s72AbB7GA0X8BmTWZ-6N-A7Q5Bg2e7hboFYnCAoedA0SOwKP53jg1ssE332ZfFyef5aTjEcgh1KvNNmHJrZkZYEvCyghtXlKXRFlNTlwubOVfJSpfOmLLIU6NjURF5pHapFUkhRfqATdpl6x4xyB0KOa5IHJdaYK2FqFxusAISNxBoAXtNc6mGxdgpr-dwqUYAKA8AxUXA3ozTrVY9ucffMr8lQFxkJF5un7Bcf1PDlCqrKUaOzhzxnGVS6CrXCXaEOxQTZ7wM2MsRTgrXMV3O6NYtt53CvZbc21B_DNjDHl4XvxpRGjC5B7y9tux_Qbx5rvARX4__vegLdv38eKE-vDt7_4Td4DjK3gEye8omOEDuGTvo7Pa5X32_AOjmO14 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+susceptibility+of+clinical+Helicobacter+pylori+isolates+and+its+eradication+by+standard+triple+therapy%3A+a+study+in+west+central+region+of+Colombia&rft.jtitle=Microbiology+spectrum&rft.au=Alvarez-Aldana%2C+Adalucy&rft.au=Fernandez+Uribe%2C+Paula+Andrea&rft.au=Mej%C3%ADa+Valencia%2C+Tatiana&rft.au=Guaca-Gonzalez%2C+Yina+Marcela&rft.date=2024-08-06&rft.issn=2165-0497&rft.eissn=2165-0497&rft.volume=12&rft.issue=8&rft.spage=e0040124&rft_id=info:doi/10.1128%2Fspectrum.00401-24&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |